Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/07/034937
CTRI/2021/07/034937
Recruiting
Phase 4

A prospective, interventional, single-arm clinical trial to evaluate the efficacy and safety of Ayurveda therapy protocol in the management of mild to moderate COVID-19 patients and its post complications

Pankajakasthuri herbal research foundation0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
Pankajakasthuri herbal research foundation
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Pankajakasthuri herbal research foundation

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients tested positive for Covid\-19 using RTPCR.
  • •2\. Willing and able to provide written informed consent prior to performing study procedures by the subject or legal guardian.

Exclusion Criteria

  • •1\. Subject or Authorized Representative is unable to provide informed consent.
  • •2\. Subject is pregnant or breastfeeding ladies.
  • •3\. Subject is of childbearing potential and has a positive pregnancy test since admission to the hospital.
  • •4\. Intra\-thoracic or intra\-abdominal surgery within the 12 hours prior to consent, or ongoing impairment of hemostasis as a result of one of these procedures.
  • •5\. A history of head trauma, spinal trauma, or other acute trauma with an increased risk of bleeding.
  • •6\. Cerebral Vascular Accident (CVA) or Intracerebral
  • •Arteriovenous Malformation (AVM), cerebral aneurysm, or mass
  • •lesions of the central nervous system or melena, hematemesis.
  • •7\. Inability to take oral medication
  • •8\. Prolonged QTc\-interval in baseline ECG ( \>500 ms)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPointTM Reperfusion SystemTM for Aspiration Embolectomy in Acute Ischemic Stroke PatientsAcute Ischemic StrokeStroke - IschaemicNeurological - Other neurological disorders
ACTRN12619000890134Route 92 Medical, Inc.15
Completed
Not Applicable
Prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-Man.severe aortic valve stenosis / severely calcified aortic valve has caused a stenosis10046973
NL-OMON55716CARDIAWAVE SA.15
Recruiting
Not Applicable
A prospective, multi-center, single-arm, clinical investigation of the safety and performance of the Sentio system in users with mixed/conductive hearing losses and single sided deafness
NL-OMON51025Oticon Medical AB15
Active, not recruiting
Not Applicable
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-001439-34-DEGenzyme Corporation1,000
Active, not recruiting
Phase 1
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple SclerosisTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2013-001439-34-ESGenzyme Corporation1,001